Skip to main content

Peer Review reports

From: The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients

Original Submission
14 Sep 2017 Submitted Original manuscript
26 Sep 2017 Reviewed Reviewer Report - John Bridgewater
8 Oct 2017 Reviewed Reviewer Report - Paul Ruff
8 Oct 2017 Reviewed Reviewer Report - Chris Karapetis
17 Oct 2017 Author responded Author comments - FRANCESCA BATTAGLIN
Resubmission - Version 2
17 Oct 2017 Submitted Manuscript version 2
11 Nov 2017 Reviewed Reviewer Report - John Bridgewater
Resubmission - Version 3
Submitted Manuscript version 3
Publishing
17 Jan 2018 Editorially accepted
25 Jan 2018 Article published 10.1186/s12885-018-4001-x

You can find further information about peer review here.

Back to article page